1. sayfa ve
Tekrarlanan kayıtlar tek bir kaynakta birleştirilmektedir.
1
Tez

Tez

Kaynak
:
Yazar(lar) :
Konu :
Biyoloji
Yıl :
2015
Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells fisetin
and hesperetin-induced effects. and CML for the first time. Moreover, the genetic networks derived from this study illuminate some of the biological pathways affected by fisetin
and hesperetin
treatment while providing
2
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yayıncı:
National Academy of Sciences
Yazar(lar) :
Konu :
Biological Sciences, Science & Mathematics, General Science
Yıl :
2001
Molecular Emergence of Acute Myeloid Leukemia during Treatment for Acute Lymphoblastic Leukemia Therapy-related
acute
myeloid leukemias (t-AML) with translocations of the MLL gene are associated with the use of topoisomerase II inhibitors. We established the emergence of the malignant clone in a
child who developed t-AML with a t(11;19) (q23;p13.3) during
treatment for
acute lymphoblastic leukemia (ALL).
3
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Pharmacology (medical), Oncology
Yıl :
2008
Childhood Acute Myeloid Leukemia Despite the use of intensive chemotherapy
and hematopoietic stem cell transplantation, approximately one-third of
children with
acute
myeloid
leukemia Instead, advances in the
treatment of
children with AML will require a greater understanding of the biology of the disease, with particular attention to More important, we must develop alternative
treatment approaches, such as agents that target specific
leukemia-associated abnormalities
and agents that Current Treatment Options in Oncology Acute Myeloid Leukemia Acute Myeloid Leukemia Patient
4
Kitap Bölümü

Kitap Bölümü
Kaynak
1:
Kaynak
2:
Kaynak
3:
Kaynak
4:
Yayıncı:
John Wiley & Sons, Ltd
Yazar(lar) :
Yıl :
2013
Acute myeloid leukemia To evaluate whether a lower dose of prophylactic cranial irradiation in
children with
acute
myeloid
leukemia (AML) is sufficient to prevent central nervous system (CNS) relapse of
leukemia. Patients with Down syndrome, CNS
leukemia at diagnosis, not in complete remission after 140 days of
treatment or those assigned to stem cell transplantation
5
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Thomas Buchner
,
Wolfgang Hiddemann
,
Wolfgang Berdel
,
Bernhard Wormann
,
Claudia Schoch
,
Helmut Loffler
,
Torsten Haferlach
,
Andrea Schumacher
,
Peter Staib
,
Leopold Balleisen
,
Andreas Gruneisen
,
Herbert Rasche
,
Carlo Aul
,
Axel Heyll
,
Eva Lengfelder
,
Wolf-Dieter Ludwig
,
Georg Maschmeyer
,
Hartmut Eimermacher
,
Jochen Karow
,
Norbert Frickhofen
,
Wolf-Dietrich Hirschmann
,
Maria-Cristina Sauerland
Konu :
Hematology
Yıl :
2002
ACUTE MYELOID LEUKEMIA: TREATMENT OVER 60 Undertreatment of older patients with
acute
myeloid
leukemia (AML) can explain, in part, their inferior outcome when compared to that of younger patients and for the duration of postremission
treatment. A questionnaire study in patients with AML showed that, according to patients’ self‐assessment, intensive
and prolonged
treatment did not result in a diminished Reviews in Clinical and Experimental Hematology
6
Kitap Bölümü

Kitap Bölümü
Kaynak
:
Yayıncı:
John Wiley & Sons, Ltd
Yazar(lar) :
Yıl :
2013
Maintenance treatment in acute myeloid leukemia The use of postremission low‐dose maintenance
treatment (MT) in
childhood
acute
myeloid
leukemia (AML) has yielded mixed results. The studies by Perel et al.
and Wells et al. suggest that MT does not appear to improve overall survival (OS). The
acute promyelocytic
leukemia (APL) 93 trial was a randomized European study evaluating postremission therapy for patients with APL.
7
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2015
Acute myeloid leukemia in infants: biology and treatment Children aged 0–2 years (i.e. infants) with
acute
myeloid
leukemia (AML) are a peculiar subgroup of patients in the
childhood AML scenario. Remarkable improvements have been achieved over the last 2 decades in the
treatment of these patients
and their outcome is becoming superimposable to that Treatment results
and toxicity data reported by major collaborative groups are also summarized
and compared. acute myeloid leukemia (AML) Treatment results
8
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2017
Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment Objective:
Leukemia is the most common pediatric malignancy
and a major cause of morbidity
and mortality in
children. Among all subtypes, a lack of consensus exists regarding the diagnosis
and
treatment of
acute
myeloid
leukemia (AML). Results: We described clonal evolution
and how it changes our view on leukemogenesis,
treatment responses,
and disease relapse. Acute Myeloid Leukemia
9
Konferans Bildirileri

Konferans Bildirileri
Kaynak
:
Yazar(lar) :
Konu :
Bioengineering, Computing and Processing
Yıl :
2007
Characterization of MYC expression in gefitinib versus Acute Myeloid Leukemia reveals novel therapeutic targets We conducted gene expression profiling
and pathway analysis of microarray data generated from a gefitinib versus M4-AML study. findings indicate that a therapeutic reduction of the human v-Myc oncoprotein correlated to molecular reversal of cell transformation within 24 hours of
treatment These targets, Src
and Jnk3, demonstrated strong interactions with gefitinib in small molecule/tyrosine kinase binding assays
and have proven critical Bioengineering,Computing and Processing 2007 IEEE 7th International Symposium on BioInformatics and BioEngineering Medical treatment acute myeloid leukemia Acute Myeloid Leukemia
10
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Cancer Research, Oncology, Hematology
Yıl :
2016
Antibody-Based Treatment of Acute Myeloid Leukemia While antibody-based therapies have emerged as clinically effective approaches for several hematologic
and solid malignancies, they have not played a significant role to date in the
treatment of
acute
myeloid
leukemia (AML). (ADCs), radio-labelled antibodies,
and immune-engaging antibodies,
and discusses the promise
and challenges associated with each. Acute myeloid leukemia
11
Dergi Makalesi

Dergi Makalesi
Kaynak
1:
Kaynak
2:
Yazar(lar) :
Konu :
Hematology, General Medicine, Hematology
Yıl :
1990
Treatment strategies in acute myeloid leukemia (AML) Chemotherapy remains the backbone of
treatment in AML. Of all adult patients 65% go into remission
and have a chance of longer survival
and of even being cured. Improved antimicrobial
treatment
and the use of hematopoietic growth factors may help making multiple-step chemotherapy practicable, thereby increasing Acute myeloid leukemia
12
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Pharmacology (medical), Oncology
Yıl :
2017
Treatment of Relapsed/Refractory Acute Myeloid Leukemia Approximately 40–45% of younger
and 10–20% of older adults with
acute
myeloid
leukemia (AML) will be cured with current standard chemotherapy. In recent years, much has been learned about the genomic
and epigenomic landscapes of AML,
and the clonal architecture of both de novo
and secondary AML In our practice, we treat most patients with relapsed/refractory AML on clinical trials, taking into consideration their prior
treatment history
and Current Treatment Options in Oncology
13
Konferans Bildirileri

Konferans Bildirileri
Kaynak
:
Yazar(lar) :
Konu :
Computing and Processing, Signal Processing and Analysis
Yıl :
2020
Convolution Neural Network Models for Acute Leukemia Diagnosis Acute
leukemia is a cancer-related to a bone marrow abnormality. It is more common in
children
and young adults. This type of
leukemia generates unusual cell growth in a short period, requiring a quick start of
treatment. Acute Lymphoid
Leukemia (ALL)
and
Acute
Myeloid
Leukemia (AML) are the main responsible for deaths caused by this cancer. Computing and Processing,Signal Processing and Analysis 2020 International Conference on Systems, Signals and Image Processing (IWSSIP) Acute Leukemia diagnosis Acute Lymphoid Leukemia Acute Myeloid Leukemia
14
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Pharmacology (medical), Pharmacology
Yıl :
2020
Novel Treatment Paradigms in Acute Myeloid Leukemia Acute
myeloid
leukemia (AML) is a heterogeneous disease marked by the presence of several driver mutations
and molecular subgroups even in a single patient Cytogenetic results
and somatic mutations are increasingly being utilized to guide use of intensive chemotherapy
and low‐intensity chemotherapy, particularly The last 3 years mark an unprecedented history in the drug development in AML with approval of 8 new drugs
and large portfolio of ongoing early
and late‐phase
15
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Pediatrics, Perinatology, and Child Health, Transplantation
Yıl :
2003
Novel treatment for refractory acute myeloid leukemia Pediatrics, Perinatology, and Child Health,Transplantation
16
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Burnusuzov Hasan A.
,
Yordanova Maya N.
,
Avramova Boryana E.
,
Yurukova Nadezhda N.
,
Bachvarov Konstantin N.
,
Muchinova Albena B.
,
Vlahova Irena H.
,
Stoyanova Angelina A.
,
Mumdzhiev Ivan N.
,
Ivanova Liliya R.
,
Spasov Neofit Y.
,
Peteva Elina Ts.
,
Belcheva Milena I.
,
Hristozova Hristina
,
Spasova Mariya I.
,
Kaleva Valeriya I.
,
Bobev Dragan
,
Konstantinov Dobrin N.
Yıl :
2018
Treatment of Childhood Acute Myeloid Leukemia in Bulgaria Background: During the last four decades the prognosis of
childhood
acute
myeloid
leukemia (AML) has been substantially improved due to an increase in complete remission (CR) rates, event-free survival (EFS)
and reduced early mortality. acute myeloid leukemia children
17
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Nephrology, Pediatrics, Perinatology and Child Health
Yıl :
2022
Acute kidney injury and childhood acute myeloid leukemia Acute kidney injury (AKI) appears to be particularly common in
children with
acute
myeloid
leukemia (AML), although the epidemiology data on this patient The objective of this study was to assess the prevalence
and factors associated with AKI in
childhood AML during chemotherapy
treatment. Age ≥ 10 years at diagnosis, impaired kidney function before
treatment,
and septic shock were strongly associated with AKI. Nephrology,Pediatrics, Perinatology and Child Health Acute kidney injury Childhood acute myeloid leukemia
18
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Pharmacology (medical), Oncology
Yıl :
2000
Acute myeloid leukemia in adults The
treatment outcome for most adults with
acute
myeloid
leukemia (AML) remains unacceptable. therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m2 as a continuous intravenous infusion over 24 hours for 7 days)
and Current Treatment Options in Oncology Acute Myeloid Leukemia
19
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Hematology
Yıl :
2012
Secondary acute myeloid leukemia occurring after successful treatment of acute promyelocytic leukemia Acute Lymphoblastic Leukemia Acute Promyelocytic Leukemia Secondary Acute Myeloid Leukemia
20
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yayıncı:
Elsevier
Yazar(lar) :
Yıl :
2017
Frontline treatment of acute myeloid leukemia in adults Recent years have highlighted significant progress in understanding the underlying genetic
and epigenetic signatures of
acute
myeloid
leukemia(AML). and for specific subsets, the improvements are even more dramatic; for example, in
acute promyelocytic
leukemia, the use of all-trans retinoic acid
and AML
treatment was also recently influenced by the discovery of the superiority of regimens with higher dose Ara-C
and nucleoside analogues compared with Acute myeloid leukemia Frontline treatment
21
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Oncology, Hematology
Yıl :
2017
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia At the therapeutic intersection between
children
and older adults, the
treatment of adolescent
and young adults (AYAs) with
acute lymphoblastic
leukemia (ALL)
and
acute
myeloid
leukemia (AML) poses unique challenges due to their dismal outcome. Intensification of supportive care while maintaining
treatment intensity could further improve outcomes of AYAs with
leukemia. Adolescents and young adults (AYAs) Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML)
22
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yayıncı:
National Academy of Sciences
Yazar(lar) :
Konu :
Biological Sciences, Science & Mathematics, General Science
Yıl :
2007
MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia Acute lymphoblastic
leukemia (ALL) is the most common
childhood cancer, whereas
acute
myeloid
leukemia (AML) is the most common
acute
leukemia in adults To understand the distinct mechanisms in leukemogenesis between ALL
and AML
and to identify markers for diagnosis
and
treatment, we performed a large-scale The differential expression patterns of these four miRNAs were validated further through large-scale real-time PCR on 98
acute
leukemia samples covering
23
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Oncology, Hematology
Yıl :
2013
Treatment results of childhood acute myeloid leukemia in Serbia We present the results of a retrospective study of
acute
myeloid
leukemia (AML)
treatment in Serbia in the period 2000–2012. Treatment was performed in four centers, two of which were located in Belgrade, one in Nis,
and one in Novi Sad. Children affected by non-
acute promyelocytic
leukemia (non-APL) subtypes received
treatment regimens derived from protocols of Berlin Frankfurt Munster Acute myeloid leukemia Children Treatment
24
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yayıncı:
Elsevier BV
Yazar(lar) :
Yıl :
2021
Targeting LSD1 for acute myeloid leukemia (AML) treatment Targeted therapy for
acute
myeloid
leukemia (AML) is an effective strategy, but currently there are very limited therapeutic targets for AML
treatment. invasion of cancer cells,
and is associated with poor prognosis. and IMG-7289 in clinical trials. AML treatment
25
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yayıncı:
Elsevier
Yazar(lar) :
Yıl :
2020
Treatment Strategies for Therapy-related Acute Myeloid Leukemia Prospective evidence for management of therapy-related
acute
myeloid
leukemia (t-AML) is limited, with evidence extrapolated from major AML trials. Optimal
treatment is challenging
and needs consideration of patient-specific, disease-specific,
and therapy-specific factors. Ongoing clinical trials focusing on
treatment of t-AML, including targeted agents
and immunotherapy, bode well for the future. Clinical Lymphoma Myeloma and Leukemia
26
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Cancer Research, Oncology
Yıl :
2007
Progress in the treatment of acute myeloid leukemia Significant progress in understanding the mechanisms leading to the development of
acute
myeloid
leukemia (AML) has led to the identification of numerous Over the same period, large trials have established standard regimens combining cytotoxic agents for the
treatment of patients with AML. newer agents with specific
and targeted activity into our standard regimens, Herein the recent developments in the diagnosis
and
treatment of AML are